FDA’s one-trial default: key factors shaping drug development | McDermott

McDermott Will & Schulte, a global law firm

COVERAGE

FDA’s one-trial default: key factors shaping drug development

March 4, 2026

Read time: 2 min

James R. Ravitz

Partner

Washington, DC

You may also like